ReviewJournal of translational autoimmunity2019
The pathogenesis of bullous skin diseases.
Review in Journal of translational autoimmunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Necrotizing Fasciitis-Severe Complication of Bullous Pemphigoid: A Systematic Review, Risk Factors, and Treatment Challenges.Medicina (Kaunas, Lithuania) · 2023Pooled it
- A Multicenter Analysis of Patients with Bullous Pemphigoid: Clinical Characteristics and Insights into Drug-Associated Disease.International journal of molecular sciences · 2026Article
- Review
- Lymphocyte Transformation Tests and Patch Tests to Identify Drugs Potentially Associated With Bullous Pemphigoid Development.International journal of dermatology · 2025Article
- Venous thromboembolism in bullous pemphigoid: current evidence from an updated systematic review.Dermatology reports · 2025Article
- Article
- A real-world data analysis of piroxicam in the FDA Adverse Event Reporting System (FAERS) database.Frontiers in medicine · 2025Article
- Repurposing Historic Drugs for Neutrophil-Mediated Inflammation in Skin Disorders.Biomolecules · 2024Review
- Article
- Paradoxical and bimodal immune-mediated dermatological side effects of TNF-α inhibitors: A comprehensive review.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Review
- Association of Human Endogenous Retrovirus-W (HERV-W) Copies with Pemphigus Vulgaris.Current molecular medicine · 2024Article
- IgG reactivity to different desmoglein-3 ectodomains in pemphigus vulgaris: novel panels for assessing disease severity.Frontiers in immunology · 2024Article
- Cytokine profiling reveals HLA-linked Th2 and Th17 driven immune activation in pemphigus vulgaris patients and genetically susceptible healthy controls.Frontiers in immunology · 2024Article
- From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid.International journal of molecular sciences · 2023Review
- Research Progress of Dihydroquercetin in the Treatment of Skin Diseases.Molecules (Basel, Switzerland) · 2023Review
- Pemphigus vulgaris after SARS-CoV-2 vaccination: A case with new-onset and two cases with severe aggravation.Dermatologic therapy · 2022Article
- Oral Health, Antimicrobials and Care for Patients With Chronic Oral Diseases - A Review of Knowledge and Treatment Strategies.Frontiers in oral health · 2022Review
- Immunotherapy for Pemphigus: Present and Future.Frontiers in medicine · 2022Review
- Occurrence of autoantibodies against skin proteins in patients with hereditary epidermolysis bullosa predisposes to development of autoimmune blistering disease.Frontiers in immunology · 2022Article
- Bullous pemphigoid: An immune disorder related to aging (Review).Experimental and therapeutic medicine · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous skin diseases are a group of dermatoses characterized by blisters and bullae in the skin and mucous membranes. The etiology and pathogenesis of bullous skin diseases are not completely clear. The most common are pemphigus and bullous pemphigoid (BP). Autoantibodies play critical roles in their pathogenesis. Abnormalities in the adhesion between keratinocytes in patients with pemphigus leads to acantholysis and formation of intra-epidermal blisters. Anti-desmoglein autoantibodies are present both in the circulation and skin lesions of patients with pemphigus. The deficient adhesion of keratinocytes to the basement membrane in BP patients gives rise to subepidermal blisters. Autoantibodies against the components of hemidesmosome can be detected in BP patients. Many novel therapeutics based on knowledge of the pathogenesis have emerged in recent years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.